News & Events
Crinetics Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024
Event Date: Crinetics Pharmaceuticals announced that it will report second quarter 2024 financial results on Thursday, August 8, 2024, after the close of the U.S. financial markets.
READ MORECrinetics Announces July 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics granted non-qualified stock option awards to purchase an aggregate of 137,900 shares of its common stock to eighteen new...
READ MOREEY Announces Scott Struthers, Ph.D., CEO and Founder of Crinetics Pharmaceuticals, as an Entrepreneur Of The Year® 2024 Pacific Southwest Award Winner
Ernst & Young LLP announces that Scott Struthers, Ph.D., founder and chief executive officer of Crinetics, was named an Entrepreneur...
READ MORECrinetics Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics granted non-qualified stock option awards to purchase an aggregate of 158,000 shares of its common stock to nine new...
READ MORECrinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing’s Syndrome (ADCS)
Crinetics announced initial findings from the development program of its second clinical product candidate, atumelnant, a novel, once-daily oral adrenocorticotropic...
READ MORECrinetics Presents New Data at ENDO 2024 that Increases that Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly
Crinetics Pharmaceuticals presents new data from its clinical development program evaluating oral, once-daily investigational paltusotine in acromegaly.
READ MORECrinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D., as Senior Vice President of Medical Affairs
Crinetics announces the appointment of Robert M. Cuddihy, M.D., as senior vice president of Medical Affairs.
READ MORECrinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts
Crinetics announces that the late-breaking abstracts accepted for presentation at ENDO 2024 were released earlier than the previously announced embargoed...
READ MORECrinetics Announces May 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics granted non-qualified stock option awards to purchase an aggregate of 176,000 shares of its common stock to fifteen new...
READ MORETransforming Endocrine Disease Treatment
Be the first to know about the advances we're making in endocrine-rooted care.